Why is Cohance Life falling/rising?

As of 11-Jun, Cohance Lifesciences Ltd is currently priced at 1,004.80, reflecting a decline of 11.4 points or 1.12%. The stock has been underperforming, having lost 6.09% over the last four days and is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Additionally, the delivery volume has decreased by 15.28% compared to the 5-day average, indicating falling investor participation. Despite a strong one-year return of 47.53%, the company has faced challenges with a significant drop in profit after tax and poor long-term growth, as evidenced by a -3.76% annual rate of operating profit growth over the last five years.
In the broader market context, the stock's short-term performance has been notably weaker than the benchmark, with a 1-week return of -0.74% compared to the Sensex's gain of +1.87%. This underperformance is compounded by the company's high valuation metrics, including a Price to Book Value of 22.7, which is considered expensive relative to its peers. While the company boasts high management efficiency and a low debt-to-equity ratio, these positives are overshadowed by declining profitability and a lack of growth, contributing to the stock's downward trend in the current market environment.